Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taurolidine vs citrate vs heparin lock solutions to prevent catheter infections in ESRD dialysis patients
IRCT20250503065575N1Phase 3Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of taurolidine, trisodium citrate and heparin in end-stage kidney disease (ESKD), catheter-associated bloodstream infection (CRBSI) and Catheter exit site infection (ESI) (4 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Incidence of catheter-related infections. Started Oct 2025; status: recruiting.
02
Drugs
taurolidinetrisodium citrateheparin
03
Conditions
end-stage kidney disease (ESKD)catheter-associated bloodstream infection (CRBSI)Catheter exit site infection (ESI)
Beyond the preview
Go deeper on IRCT20250503065575N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250503065575N1.